1711202

Verapamil hydrochloride

United States Pharmacopeia (USP) Reference Standard

• Synonyme(s) : (±)-Verapamil hydrochloride, 5-[N-(3,4-Dimethoxyphenylethyl)methylamino]-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile hydrochloride
• Formule linéaire : (CH₃O)₂C₆H₃CH₂CH₂N(CH₃)(CH₂)₃C[C₆H₃(OCH₃)₂][CH(CH₃)₂]CN · HCl
• CAS Number: 152-11-4
• Poids moléculaire : 491.06
• Beilstein: 3647093
• Numéro CE : 205-800-5
• Numéro MDL: MFCD00055208
• Code UNSPSC : 41116107
• ID de substance PubChem : 329751490
• Nomenclature NACRES : NA.24

Propriétés

• Qualité: pharmaceutical primary standard
• Famille d'API: verapamil
• Fabricant/nom de marque: USP
• Pf: 142 °C (dec.) (lit.)
• Application(s): pharmaceutical (small molecule)
• Format: neat
• Chaîne SMILES: Cl.COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2ccc(OC)c(OC)c2)cc1OC
• InChI: 1S/C27H38N2O4.ClH/c1-20(2)27(19-28,22-10-12-24(31-5)26(18-22)33-7)14-8-15-29(3)16-13-21-9-11-23(30-4)25(17-21)32-6;/h9-12,17-18,20H,8,13-16H2,1-7H3;1H
• Clé InChI: DOQPXTMNIUCOSY-UHFFFAOYSA-N
• Informations sur le gène: human ... CACNA1C(775), CACNA1D(776), CACNA1F(778), CACNA1S(779)

Description

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Verapamil hydrochloride USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:

• Verapamil Hydrochloride Injection
• Verapamil Hydrochloride Tablets
• Verapamil Hydrochloride Extended-Release Capsules
• Verapamil Hydrochloride Extended-Release Tablets
• Verapamil Hydrochloride Compounded Oral Solution
• Verapamil Hydrochloride Compounded Oral Suspension

Actions biochimiques/physiologiques

α₁-adrenoceptor antagonist; L-type calcium channel blocker.

α₁-adrenoceptor antagonist; L-type calcium channel blocker. Blocks L-type Ca²⁺ channels in smooth and cardiac muscle, induces apoptosis of human primary and metastatic colon adenocarcinoma cells in vitro. Drug resistance reversal agent acting on Pgp, e.g. decrease renal tubule elimination of digoxin. Increases basal ATPase activity of Pgp. Substrate of Cyp3A4 and CYP2C6.

Remarque sur l'analyse

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Autres remarques

Sales restrictions may apply.

Informations sur la sécurité

• Pictogrammes: GHS06,GHS09
• Mention d'avertissement: Danger
• Mentions de danger: H301,H411
• Conseils de prudence: P264 - P273 - P301 + P310 - P391 - P405 - P501
• Classification des risques: Acute Tox. 3 Oral - Aquatic Chronic 2
• Code de la classe de stockage: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• Classe de danger pour l'eau (WGK): WGK 3
• Point d'éclair (°F): Not applicable
• Point d'éclair (°C): Not applicable